Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-1931

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 71335-1931). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Biso Api Structure (Api Pic New1)

Biso Api Structure (Api Pic New1)
Chemical structure diagram of the active ingredients Bisoprolol Fumarate and Hydrochlorothiazide. The image depicts molecular formulas showing Bisoprolol's substituted aromatic ring and fumarate's carboxylic acid groups.*
FDA Label Image

Hctz Api Structure (Api Pic New2)

Hctz Api Structure (Api Pic New2)
Chemical structure diagram of the active ingredient bisoprolol fumarate, showing a benzene ring with attached chlorine, sulfonamide, and other functional groups as labeled in the structure.*
FDA Label Image

Label (Lbl713351931)

Label (Lbl713351931)
Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide 2.5 mg / 6.25 mg film coated tablets. The label indicates the product is packaged by Bryant Ranch Prepack in Burbank, CA. It includes a lot number and storage instructions to keep at room temperature 20°-25°C (68°-77°F). The label compares the product to Ziac 2.5/6.25 mg tablet by Edenbridge Pharmaceuticals LLC and shows the NDC 71335-1931.*
FDA Label Image

Table 1 (Table 1 New)

Table 1 (Table 1 New)
Data table presenting the mean decrease in sitting systolic/diastolic blood pressure (BP) and heart rate (HR) after 3-4 weeks from two studies on different dosages of Bisoprolol Fumarate and Hydrochlorothiazide versus placebo. The table includes sample sizes, total BP and HR changes, and drug effects for various dose combinations.*
FDA Label Image

Table-3 (Table 3 New)

Table-3 (Table 3 New)
Table presenting percentages of patients with adverse experiences related to Bisoprolol Fumarate and Hydrochlorothiazide (B2.5-40/H6.25 and B2.5-10/H6.25) compared to placebo. Adverse experiences are grouped by body system including cardiovascular, respiratory, CNS, musculoskeletal, psychiatric, and gastrointestinal. Data are shown for all adverse experiences and drug-related adverse experiences.*
FDA Label Image

Table-2 (Table New 2)

Table-2 (Table New 2)
A data table titled "Serum Potassium Data from U.S. Placebo Controlled Studies" comparing potassium levels and hypokalemia incidence across placebo and various Bisoprolol Fumarate and Hydrochlorothiazide doses. Columns show sample sizes and mean potassium changes in mEq/L, highlighting potassium stability and hypokalemia percentages for different dosage groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.